Fatty Liver
5 videos · updated daily
12:01 Noninvasive Testing and MASH Clinical Trials
Winston Dunn, MD, of the University of Kansas Medical Center tells Xtalks how noninvasive testing and risk-stratification tools could shape MASH clinical trials, why fibrosis may weigh more in trial design and how machine learning could aid risk assessment.
52:08 Webinar Highlighting Oramed's Positive Phase 2 NASH Data
Professor Yaron Ilan, M.D., of Hebrew University-Hadassah Medical Center and Joel Neutel, M.D., of the Orange County Research Center discuss Oramed's Phase 2 data for ORMD-0801 in NASH.
3:44 Efimosfermin Alfa for MASH: Phase 2 Results
Mazen Noureddin, MD, of Houston Methodist tells HCPLive about phase 2 data presented at DDW 2025 on once-monthly efimosfermin alfa, an FGF21 analogue, in 84 patients with biopsy-confirmed MASH and F2-F3 fibrosis.
7:32 ESSENCE: Semaglutide in MASH
Arun Sanyal of Virginia Commonwealth University discusses the interim week-72 analysis of the phase 3 ESSENCE trial of once-weekly semaglutide 2.4 mg versus placebo in 1,197 patients with biopsy-confirmed MASH and F2-F3 fibrosis, for Radcliffe Cardiology.
3:10 Clinical Trials of Resmetirom to Treat Fatty Liver Disease
Resmetirom in the form of a pill could reverse the effects of Fatty Liver Disease by targeting the thyroid hormone in the liver to get rid of liver fat, according to this local news report.